Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764475 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT03764475 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 332 participants.
The verdict
NCT03764475, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits will include assessments for clinical safety, application site reactions, and disease improvement or progression.
Interventions
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764475
The ClinicalTrials.gov registry entry for NCT03764475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roflumilast is the first listed.
NCT03764475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03764475 about?
NCT03764475 is a clinical study titled "Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis". This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits...
What is the current status of trial NCT03764475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2018-12-18. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT03764475?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT03764475?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.